A New Alternative for Second-Line Treatment

The second-line treatment market for clear cell renal cell carcinoma (ccRCC) is in urgent need of alternatives for patients who have failed prior treatment with existing targeted therapies and immune checkpoint inhibitors. The KEYMAKER-U03 substudy 03B clinical trial was designed to explore new treatment combinations in patients who had progressed after treatment with immune checkpoint inhibitors (PD-1 inhibitors) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-TKIs). Given that this study focuses on a difficult-to-treat patient population that has developed resistance to standard therapies, it can serve as an important milestone in addressing the unmet medical needs in later lines of therapy.

The Potent Efficacy of Welireg and Lenvima Combination

The most notable results in this trial came from the group treated with Welireg (belzutifan), an oral HIF-2α inhibitor, and Lenvima (lenvatinib), a multi-targeted kinase inhibitor. The analysis showed that this combination therapy achieved an objective response rate (ORR) of 46.9% and a median progression-free survival (PFS) of 12.5 months, demonstrating potent anti-tumor activity. By simultaneously blocking the HIF-2α pathway, which is activated to mimic the oxygen-deprived state of tumors, and inhibiting angiogenesis, the complementary mechanism effectively targets tumor cells that have developed resistance to previous treatments.

Differentiation from Single Immune Checkpoint Inhibitor Combinations

In contrast, other combination therapies based on Keytruda (pembrolizumab) showed relatively poor or less-than-expected efficacy. In particular, the combination with favezelimab, an anti-LAG-3 therapy, or MK-4830, an anti-ILT4 therapy, did not show significant responses, revealing the limitations of immune regulation within the tumor microenvironment. This clearly demonstrates the clinical differentiation that, in later-line renal cell carcinoma patients, a combination of targeted therapies that simultaneously target metabolic and angiogenic pathways is much more effective than simple multiple immune checkpoint inhibition.

Overcoming the Challenge of Adverse Effects

However, the safety profile and management of adverse effects, which are somewhat overshadowed by the high efficacy, are among the key challenges that must be overcome in the future commercialization process. While manageable toxicity was reported in the Welireg and Lenvima combination group, some patients experienced grade 3-5 treatment-related adverse events, such as cerebral hemorrhage and intracranial hemorrhage. These serious adverse reactions may hinder the expansion of prescriptions in the renal cell carcinoma market, where there are many elderly patients, and will require clinicians to implement thorough monitoring protocols and dosing guidelines.

Global Partnership and Market Prospects

This clinical result has further solidified the strategic partnership between MSD and Eisai, and is expected to strengthen their position in the high-value later-line market. In the global advanced renal cell carcinoma market, which is worth approximately $8 billion annually, the two companies have expanded their portfolio from the existing Keytruda and Lenvima combination to include new combinations based on Welireg. In particular, the potential as a next-generation treatment option targeting resistant patients will be a key weapon in maintaining market leadership and fending off strong competitors such as Pfizer and AstraZeneca.